Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 2, pp 271–273 | Cite as

Over compliance with capecitabine oral chemotherapy

  • Jennifer Allen
  • Steve Williamson
Case Report

Abstract

Case

A case study of a patient who over complied with adjuvant capecitabine monotherapy on several occasions is described. The patient suffered worsening side effects, predominantly palmar plantar erythrodysesthesia which resulted in dose reduction and delay. The patient had disregarded advice to stop taking the capecitabine as he perceived it as “important to fight his cancer”. The patient refused review with a psychologist.

Conclusion

There is a lack of evidence regarding the issue of over compliance. Pharmacists should consider discussing patient’s attitudes towards taking their medication and its importance to them in treating their cancer. Tools that are used to assess non-compliance could be utilised to identify patients who over comply. Further research is required to gain further understanding of the psychological factors behind patient’s decisions to over comply with treatment.

Keywords

Adherence Adverse drug reactions Cancer Capecitabine Compliance Oral chemotherapy 

Notes

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    Simchowitz B, Shiman L, Spencer J, Brouillard D, Gross A, Connor M, et al. Perceptions and experiences of patients receiving oral chemotherapy. Clin J Oncol Nurs. 2010;14(4):447–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.PubMedGoogle Scholar
  3. 3.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Winkeljohn D. Adherence to oral cancer therapies: nursing interventions. Clin J Oncol Nurs. 2010;14(4):461–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Partridge AH, Wang PS, Winer PS, Avorn J, Weingart SN. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Timmers L, Boons C, Mangnus D, Moes J, Swart E, Boven E, et al. The use of erlotinib in daily practice: a study on adherence and patients’ experiences. BMC Cancer. 2011;11:284.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Nilsson J, Andersson K, Bergkvist A, Björkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care. 2006;15(3):235–7.CrossRefGoogle Scholar
  8. 8.
    Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Oncology Nursing Society. adherence to oral therapies for cancer: helping your patient stay on course toolkit. http://www.ons.org/ClinicalResources/OralTherapies/Toolkit. Accessed 5th December 2013.
  10. 10.
    Timmers L, Swart E, Boons C, Mangnus D, van de Ven PM, Godefridus P, et al. The use of capecitabine in daily practice: a study on adherence and patients’ experiences. Patient Prefer Adher. 2012;6:741–8.CrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  1. 1.Pharmacy DepartmentNorthumbria Healthcare NHS TrustNorth ShieldsUK

Personalised recommendations